DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF, 2 NDC API

1 API Suppliers
1 USDMF
2 NDC API

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 South Africa

1 FDF Dossiers
1 South Africa

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

1INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 571170-77-9, Mk 0524, Mk-0524, Cardaptive, Cordaptive, Chembl426559

Molecular Formula

C₂₁H₁₉ClFNO₄S

Molecular Weight

435.9 g/mol

InChI Key

NXFFJDQHYLNEJK-CYBMUJFWSA-N

FDA UNII

G7N11T8O78

Laropiprant is a prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of DP1, a G-protein coupled receptor. Via competing with prostaglandin D2 (PG D2) for binding to DP1, this agent prevents PG D2-induced vasodilation and increased blood flow. As niacin induces the synthesis of PG D2, predominantly in the skin, administration of laropiprant may prevent niacin-induced vasodilation in the skin and facial flushing.

1 2D Structure

LAROPIPRANT

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid

2.1.2 InChI

InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1

2.1.3 InChI Key

NXFFJDQHYLNEJK-CYBMUJFWSA-N

2.1.4 Canonical SMILES

CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F

2.1.5 Isomeric SMILES

CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F

2.2 Other Identifiers

2.2.1 UNII

G7N11T8O78

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl Acetic Acid

2. Mk-0524

2.3.2 Depositor-Supplied Synonyms

1. 571170-77-9

2. Mk 0524

3. Mk-0524

4. Cardaptive

5. Cordaptive

6. Chembl426559

7. G7n11t8o78

8. 2-[(3r)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic Acid

9. ((3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid

10. (-)-((3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid

11. 2-[(3r)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1h,2h,3h,4h-cyclopenta[b]indol-3-yl]acetic Acid

12. Cyclopent(b)indole-3-acetic Acid, 4-((4-chlorophenyl)methyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3r)-

13. Laropiprant [usan]

14. Tedaptive

15. Unii-g7n11t8o78

16. Laropiprant [usan:inn:ban]

17. Cyclopent[b]indole-3-acetic Acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3r)-

18. [14c]-laropiprant

19. Laropiprant [mi]

20. Laropiprant [inn]

21. Laropiprant (inn/usan)

22. Laropiprant; Mk-0524

23. Laropiprant (mk-0524)

24. Laropiprant [mart.]

25. Laropiprant [who-dd]

26. Schembl991107

27. Laropiprant [ema Epar]

28. Amot0189

29. Gtpl3356

30. Dtxsid60205756

31. Chebi:135942

32. Bcpp000161

33. Bcp02136

34. Ex-a2099

35. Zinc3961849

36. Bdbm50205275

37. Laropiprant,cas:571170-77-9

38. Mk0524

39. Akos030526850

40. Am81247

41. At34794

42. Bcp9000944

43. Cardaptive; Mk 0524; Mk-0524

44. Cs-0539

45. Db11629

46. Ncgc00345790-10

47. Ac-35835

48. As-17012

49. Hy-50175

50. A25234

51. D08940

52. Q412291

53. [(3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid

54. Laropiprant;(r)-2-(4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₁₉ClFNO₄S
Molecular Weight	435.9 g/mol
XLogP3	3.5
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	5
Exact Mass	435.0707351 g/mol
Monoisotopic Mass	435.0707351 g/mol
Topological Polar Surface Area	84.8 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	721
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1